yemenjmedYemen Journal of MedicinecoVolume 1 Issue 2MultidisciplinaryEnglishJuly - December 2022NNY20250329ArticleA case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?EnglishY103107Theeb OsamaSulaimanEnglishNAhmed K AYasinEnglishYAbdellatifIsmailEnglishY10.32677/yjm.v1i2.3684We reported a case of cyclophosphamide (CYP)-induced posterior reversible encephalopathy syndrome (PRES) in a 26-year-old previously healthy male patient who was presented to the emergency department with a history of fever, shortness of breath, and hemoptysis. After extensive investigations, including bronchoscopy and autoimmune screening, he was diagnosed with renalpulmonary syndrome. The diagnosis of CYP-related PRES was based on the development of neurological clinical picture supported by magnetic resonance imaging findings. The dose of CYP was decreased to 75 mg/day, and the patient’s symptoms improved after 3 days.EnglishAntineutrophil cytoplasmic antibody, Cyclophosphamide, Posterior reversible encephalopathy syndrome, Renalpulmonary diseasehttps://yemenjmed.com/admin/abstract?id=34References16191. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.2. Hinduja A. Posterior reversible encephalopathy syndrome: Clinical features and outcome. Front Neurol 2020;11:71.3. Pan D, Sabharwal B, Vallejo F. Posterior reversible encephalopathy syndrome secondary to cyclophosphamide in the treatment of pulmonary renal syndrome. Chest 2017;152:A367.4. Ganesh K, Nair RR, Kurian G, et al. Posterior reversible encephalopathy syndrome in kidney disease. Kidney Int Rep 2017;3:502-7.5. Ge YT, Liao JL, Liang W, et al. Anti-glomerular basement membrane disease combined with IgA nephropathy complicated with reversible posterior leukoencephalopathy syndrome: An unusual case. Am J Case Rep 2015;16:849-53.6. Shrestha GS, Nepal G, Basnet B, et al. Cyclophosphamide-induced posterior reversible encephalopathy syndrome: A case report. Neurol Clin Neurosci 2021;9:349-52.7. Scailteux LM, Hudier L, Renaudineau E, et al. Posterior reversible encephalopathy syndrome after a first injection of cyclophosphamide: A case report. J Pharmacovigil 2015;3:163.8. Cha B, Kim DY, Jang H, et al. Unusual case of posterior reversible encephalopathy syndrome in a patient with anti-glomerular basement membrane antibody glomerulonephritis: A case report and review of the literature. Electrolyte Blood Press 2017;15:12-6.9. Lee CH, Lee YM, Ahn SH, et al. Cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with lupus nephritis. J Rheum Dis 2013;20:103-7.10. Nisar T, Alchaki AR, Feinstein E. A rare case of cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with antiGBM vasculitis, and review of current literature. Case Rep Neurol Med 2019;2019:2418597.11. Camara-Lemarroy CR, Cruz-Moreno MA, Gamboa-Sarquis RN, et al. Goodpasture syndrome and posterior reversible encephalopathy syndrome. J Neurol Sci 2015;354:135-7.12. Mohammed E, Ramrattan A, Santoriello D. Posterior reversible encephalopathy syndrome secondary to cyclophosphamide. Caribb Med J 2020;82:1-4.13. Jabrane M, Ait Lahcen Z, Fadili W, et al. A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide. Rheumatol Int 2015;35:935-8.14. Buttar C, Lakhdar S, Castillo FC, et al. Cyclophosphamide induced posterior reversible encephalopathy syndrome (PRES) in a patient with lupus nephritis. Clin Med Rev Case Rep 2021;8:354.15. Jayaweera JL, Withana MR, Dalpatadu CK, et al. Cyclophosphamideinduced posterior reversible encephalopathy syndrome (PRES): A case report. J Med Case Rep 2014;8:442.16. Rahmanzadeh R, Rahmanzade R, Zabihiyeganeh M. Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease: A case report. J Med Case Rep 2016;10:145.17. Abenza-Abildua MJ, Fuentes B, Diaz D, et al. Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome. BMJ Case Rep 2009;2009:bcr07.2008.0467.18. Kim Y, Kwak J, Jung S, et al. Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report. World J Clin Cases 2021;9:6130-7.19. Bartynski WS. Posterior reversible encephalopathy syndrome, Part 2: Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008;29:1043-9.20. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 2010;85:427-32.21. Camara-Lemarroy CR, Lara-Campos JG, Perez-Contreras E, et al. Takayasuand;rsquo;s arteritis and posterior reversible encephalopathy syndrome: A case-based review. Clin Rheumatol 2013;32:409-15.22. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversibleand;nbsp;encephalopathy syndrome: Prognostic utility of quantitative diffusionweighted MR images. Am J Neuroradiol 2002;23:1038-48.23. Wu Q, Marescaux C, Wolff V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010;64:169-77.24. Kalaiselvan MS, Renuka MK, Arunkumar AS. Clinical features and outcomes of patients with posterior reversible encephalopathy syndrome. Indian J Crit Care Med 2017;21:453-6.